Pancreatic polypeptide
The pancreatic hormone that signals fullness, cut food intake when infused, and stayed a research tool because it clears in minutes
Pancreatic polypeptide is made by cells of the pancreatic islets and released into the blood after a meal, more the larger the meal, under the control of the vagus nerve. It belongs to the neuropeptide Y family and acts mainly on the Y4 receptor, signalling fullness to the brain. Infused into volunteers it reduced appetite and food intake; its level is low in obesity and used as a test of vagal nerve function. Its half-life of a few minutes is why it never became a drug.
Used in human trials: 10 pmol/kg/min, Continuous infusion, Intravenous (Study: healthy volunteers, appetite (10 volunteers, crossover)) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Pancreatic polypeptide, PP, is a 36-amino-acid hormone made by a distinct set of cells in the pancreatic islets. It is released into the blood within minutes of a meal, and more after a larger or more protein-rich meal. Its release is driven by the vagus nerve: blocking that nerve with atropine, or cutting it, sharply reduces the response, and acetylcholine triggers release from the isolated pancreas.
PP is one of the neuropeptide Y family, alongside PYY and neuropeptide Y, and acts mainly through the Y4 receptor. In the hypothalamus this signals fullness; in the pancreas PP briefly lowers insulin release. A 2023 review frames it as a candidate appetite target whose main drawback is how fast it disappears from the blood.
Giving PP to people reduces eating. In ten volunteers, an infusion at 10 pmol/kg/min cut the energy eaten at a buffet two hours later by about 22%, and the effect lasted: 24-hour intake fell about 25%. A later study halved the rate to 5 pmol/kg/min in 14 lean volunteers and still saw an 11% fall in intake and less hunger. At higher rates PP let volunteers tolerate a larger tube-fed volume before feeling full, without changing how the stomach relaxed or emptied. In Prader-Willi syndrome, where PP is deficient and overeating severe, infusions restored normal PP levels and reduced food intake by about 12%.
Its half-life is the catch. Infused bovine PP disappeared with a half-time of about seven minutes, and the 2023 review names that short circulating life as the main barrier to using PP itself as a medicine; longer-lasting versions would be needed.
As a marker, PP is informative. It is low in obesity, both fasting and after a meal, and its rise after sham feeding is used to test vagal nerve function, though up to 30% of healthy people have a low response. A blunted PP response to a meal is being studied to tell diabetes caused by pancreatic cancer from ordinary type 2 diabetes. High PP levels occur with some pancreatic endocrine tumours.
Mechanism of Action
Pancreatic polypeptide is released from the islets after meals under vagal control and acts mainly on Y4 receptors, signalling fullness to the brain and briefly lowering insulin in the pancreas.
Fullness through Y4 receptors
Acting on hypothalamic Y4 receptors, PP induces satiety in animals and people; infused, it reduced appetite and food intake.
Vagal control of release
PP release after a meal is driven by the vagus nerve; it is blunted by atropine and abolished by vagotomy, and its response is used to test vagal function.
Short life in blood
PP clears with a half-time of about seven minutes, the main reason the hormone itself has not been developed as a drug.
Published Research
These are studies of pancreatic polypeptide read from their PubMed abstracts: the human infusion studies of appetite and gastric function, its pharmacokinetics, studies of how it is released and what its level marks, and a 2023 review. Drugs and analogues built on it are not carded here.
PP infusion cuts appetite and food intake
In a randomised, double-blind, placebo-controlled crossover study of ten healthy volunteers, an intravenous infusion of PP at 10 pmol/kg/min reduced energy intake at a buffet lunch two hours later by 21.8%. The effect lasted: cumulative 24-hour energy intake fell 25.3%, measured by food diaries into the next morning.
Lower dose still reduces intake
In 14 lean fasted volunteers, a 90-minute infusion of PP at 5 pmol/kg/min, half the rate of the earlier study, cut energy intake at a buffet lunch by 11% against saline and lowered pre-meal hunger. Plasma PP stayed within the range seen with pancreatic tumours rather than above it.
Higher doses raise the volume tolerated
In 12 healthy volunteers given 0, 3 or 10 pmol/kg/min of PP before a tube-fed nutrient drink, PP increased the volume ingested before maximum fullness (886 to about 1,050 ml) without changing how the stomach relaxed; in a separate test it did not change gastric emptying, so the effect was not through stomach motility.
PP infusions reduce eating in Prader-Willi syndrome
Patients with Prader-Willi syndrome, who have deficient PP and severe overeating, were given intravenous PP (50 pmol/kg/h for 90 minutes) morning and afternoon. Infusions restored normal PP levels and reduced food intake overall by about 12% in a free-feeding test, an effect seen in the female subjects.
Pharmacokinetics: cleared in about seven minutes
Pure bovine PP infused into 23 healthy subjects at 1, 3 and 5 pmol/kg/min produced steady plasma levels; on stopping, PP disappeared with a half-time of 6.9 minutes, with a clearance of 5.1 ml/kg per minute and a distribution volume of 51 ml/kg.
Release is driven by the vagus nerve
PP rose with insulin-induced low blood sugar in healthy people and duodenal ulcer patients; atropine blunted the response and vagotomy abolished it. Electrical vagal stimulation in pigs raised portal PP within 30 seconds, and acetylcholine released PP from the isolated pancreas, all blocked by atropine.
A weak PP response marks early autonomic neuropathy
In 18 juvenile diabetics, the PP response to insulin-induced low blood sugar was severely blunted in those with autonomic neuropathy and normal in those without; it fell with longer diabetes duration and tracked an abnormal vibration sense, marking early autonomic nerve damage.
As a vagal function test, better when normal than abnormal
In 24 controls, 40 patients with diabetic gastroenteropathy and 40 with non-ulcer dyspepsia, the PP rise to sham feeding agreed with heart-based vagal tests but was reduced in up to 30% of healthy controls, limiting its use to detect nerve injury; a normal response was more informative than an abnormal one, and it did not track gastric emptying.
Low pancreatic polypeptide in obesity
Fasting PP was lower in 22 obese subjects than in 22 normal-weight controls, and the rise during the second phase of a protein-rich meal was reduced, pointing to a possible role for low PP in obesity.
Exaggerated PP secretion in Pima Indians
Pima Indian children, a group with high rates of obesity and diabetes, had about 57% higher fasting PP than matched Caucasian children, and Pima adults had a larger early PP rise after a meal, which the authors read as an increased parasympathetic drive to the pancreas.
Higher PP in Pima Indians regardless of weight
In 62 Pima Indians and 22 Caucasians, fasting and post-meal PP did not differ among non-obese, obese and diabetic Pimas but were higher in Pimas than in Caucasians overall, and PP rose with age in both groups.
Blunted PP response in pancreatic-cancer diabetes
In 18 subjects with new-onset diabetes, the PP rise after a mixed meal was smaller in diabetes from pancreatic cancer than in type 2 diabetes at 30 minutes, and smallest when the tumour sat in the head of the pancreas, suggesting the test might help flag pancreatic cancer.
PP suppresses motilin but not metabolism
Infused into healthy fasting subjects at 1 and 4 pmol/kg/min, PP cut fasting motilin to about 20% of baseline but did not change insulin, glucagon, gastrin, secretin or several metabolites, so its clearest action here was an indirect one on digestive motility through motilin.
Measured by mass spectrometry
A mass-spectrometry method identified 23 circulating forms of human PP, several glycosylated, and gave results clinically equivalent to the established immunoassay while detecting the expected rise after sham feeding; measuring the modified forms may add clinical value.
Pancreatic polypeptide revisited
The review summarises PP as an NPY-family hormone secreted from the islets that induces fullness through hypothalamic Y4 receptors in animals and people and has an acute insulin-lowering effect; it names the short circulating half-life as the main barrier and argues that long-acting, enzyme-resistant forms are needed to test the Y4 receptor as an obesity and diabetes target.
Dosing Data
Pancreatic polypeptide is not approved as a medicine anywhere. These are research infusion rates from published human studies, as stated in their abstracts; none was a treatment course.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Pancreatic polypeptide is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intravenous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.
Source: the route and amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Pancreatic polypeptide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Pancreatic polypeptide stays intact once mixed.
How it is taken
As it was given in human studies: Intravenous (Continuous infusion; Study: healthy volunteers, appetite (10 volunteers, crossover)).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 6.9 minutes after a 60-minute infusion in 23 healthy subjects (PMID 568585). After about five half-lives almost none is left.
How long the doses were given: Study: healthy volunteers, appetite (10 volunteers, crossover): 90 minutes; Study: lean volunteers, lower dose (14 volunteers): 90 minutes; Study: Prader-Willi syndrome: 90 minutes each.
When effects appear: unknown; no source on this page gives a time to effect for Pancreatic polypeptide. Results reported in the studies are under Published Research.
Source: half-life: PMID 568585; Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Infusions reduced appetite and hunger, the intended effect, with no adverse events singled out in the abstracts read; No safety data beyond single infusions lasting up to 90 minutes. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Pancreatic polypeptide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the short infusion studies above, which reported little on safety”).
Interactions
Unknown: a PubMed search for human interaction studies of Pancreatic polypeptide (reviewed 2026-10-28) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Pancreatic polypeptide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Pancreatic polypeptide's expected mass, 4,181.8 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Research Chemical (Not a medicine anywhere in the sources read). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the short infusion studies above, which reported little on safety.
Contraindications & Cautions
No product label exists. These cautions follow from the evidence.
Legal Status
Pancreatic polypeptide is a research peptide and diagnostic marker; it is not approved as a medicine anywhere in the sources read.
Frequently Asked Questions
?What does pancreatic polypeptide do?
Released from the pancreas after a meal, it signals fullness to the brain through Y4 receptors and briefly lowers insulin release. Infused into people it reduced appetite and food intake.
?Could it be a weight-loss drug?
Infusions cut food intake by 11 to 25% in volunteers, but the hormone clears from blood in about seven minutes, so a long-acting version would be needed; a 2023 review names that short half-life as the main barrier.
?Why is pancreatic polypeptide used as a vagal nerve test?
Its release after a meal or sham feeding is driven by the vagus nerve, so a poor rise points to vagal nerve damage, though up to 30% of healthy people also have a low response.
?Is its level changed in disease?
It is low in obesity, high with some pancreatic endocrine tumours, deficient in Prader-Willi syndrome, and blunted after meals in diabetes caused by pancreatic cancer.
?How long does it last in the blood?
About seven minutes: infused bovine PP disappeared with a half-time of 6.9 minutes in 23 healthy subjects.
References
- [clinical-trial] Batterham RL, et al. "Pancreatic polypeptide reduces appetite and food intake in humans." J Clin Endocrinol Metab, 2003;88(8):3989-92. PMID: 12915697.
- [clinical-trial] Jesudason DR, et al. "Low-dose pancreatic polypeptide inhibits food intake in man." Br J Nutr, 2007;97(3):426-9. PMID: 17313701.
- [clinical-trial] Verbeure W, et al. "Supraphysiological effects of pancreatic polypeptide on gastric motor function and nutrient tolerance in humans." Physiol Rep, 2021;9(17):e15002. PMID: 34435472.
- [clinical-trial] Berntson GG, et al. "Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome." Peptides, 1993;14(3):497-503. PMID: 8332550.
- [pubmed] Adrian TE, et al. "Pharmacokinetics of pancreatic polypeptide in man." Gut, 1978;19(10):907-9. PMID: 568585.
- [pubmed] Schwartz TW, et al. "Vagal, cholinergic regulation of pancreatic polypeptide secretion." J Clin Invest, 1978;61(3):781-9. PMID: 641155.
- [pubmed] Krarup T, et al. "Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics." Br Med J, 1979;2(6204):1544-6. PMID: 394798.
- [pubmed] Desai A, et al. "Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia." Neurogastroenterol Motil, 2020;32(2):e13744. PMID: 31642143.
- [pubmed] Lassmann V, et al. "Low plasma levels of pancreatic polypeptide in obesity." Diabetes, 1980;29(6):428-30. PMID: 7380112.
- [pubmed] Weyer C, et al. "Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?." Metabolism, 2001;50(2):223-30. PMID: 11229433.
- [pubmed] Gingerich RL, et al. "Pancreatic polypeptide in Pima Indians: the influence of obesity and diabetes." Metabolism, 1985;34(1):25-9. PMID: 3965859.
- [pubmed] Hart PA, et al. "Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus." Pancreatology, 2015;15(2):162-6. PMID: 25766398.
- [clinical-trial] Adrian TE, et al. "Effects of pancreatic polypeptide on motilin and circulating metabolites in man." Eur J Clin Invest, 1980;10(3):235-40. PMID: 6783420.
- [pubmed] Maus A, et al. "Identification, Measurement, and Assessment of the Clinical Utility of Human Pancreatic Polypeptide by Liquid Chromatography-Tandem Mass Spectrometry." J Proteome Res, 2023;22(4):1322-1330. PMID: 36880754.
- [review] Zhu W, et al. "Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes." Peptides, 2023;160:170923. PMID: 36509169.
- [pubmed] Janssens J, et al. "Pancreatic polypeptide is not involved in the regulation of the migrating motor complex in man." Regul Pept, 1982;3(1):41-9. PMID: 7054861.
- [other] UniProt P01298: PAHO_HUMAN, pancreatic polypeptide prohormone; peptide 30-65 is pancreatic polypeptide, ending in a tyrosine amide. Read October 28, 2026. https://www.uniprot.org/uniprotkb/P01298/entry
Sources & Citations
Every study on this page was read from its PubMed record on October 28, 2026. Regulatory status comes from Drugs@FDA (openFDA) and the EMA medicines list, read the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.